RenovoRx, Inc. - RNXT STOCK NEWS

RenovoRx (Nasdaq: RNXT) has announced the enrollment of the first patient at the University of Nebraska Medical Center (UNMC) for its ongoing Phase III TIGeR-PaC clinical trial. The study is evaluating RenovoGem™, a novel therapy for Locally Advanced Pancreatic Cancer (LAPC) using the TAMP™ (Trans-Arterial Micro-Perfusion) platform. This approach aims to deliver gemcitabine chemotherapy directly to the tumor site, potentially overcoming the challenge of drug penetration through the tumor's protective scar tissue.

The trial compares TAMP therapy to standard intravenous chemotherapy. UNMC, which joined the study in June 2024, is expected to help drive enrollment to completion by next year. The TIGeR-PaC study is currently enrolling unresectable LAPC patients across multiple US sites, reflecting RenovoRx's commitment to improving outcomes for patients with difficult-to-treat pancreatic cancer.

RenovoRx (Nasdaq: RNXT) announced the publication of positive early-stage clinical data for its Trans-Arterial Micro-Perfusion (TAMP) therapy platform in The Oncologist. The study focused on treating Locally Advanced Pancreatic Cancer (LAPC) using TAMP to deliver gemcitabine. Key findings include:

1. Overall Survival (OS) of 27.1 months for LAPC patients with prior radiation treated with TAMP-delivered chemotherapy.

2. Median OS of 12.6 months for all 35 evaluable LAPC patients.

3. TAMP is currently being evaluated in a Phase III clinical trial for LAPC treatment.

The study suggests TAMP could potentially offer a safer, more effective treatment option for LAPC compared to standard systemic chemotherapy, with fewer side effects.

RenovoRx announces the acceptance of their manuscript, titled “Treatment of Locally Advanced Pancreatic Cancer (LAPC) Using Localized Trans-Arterial Micro Perfusion (TAMP™) of Gemcitabine: Combined Analysis of RR1 and RR2,” for publication in The Oncologist, a prestigious peer-reviewed journal. The manuscript, authored by Dr. Hassan Hatoum, will be in the Summer 2024 issue and presents clinical data on the survival of LAPC patients treated with RenovoRx's TAMP therapy platform. This data stems from early Phase I/II dose escalation safety study (RR1) and a post-marketing observational registry study (RR2). TAMP is also under evaluation in the ongoing pivotal Phase III TIGeR-PaC study, comparing its efficacy to the standard intravenous chemotherapy in LAPC treatment.

RenovoRx has announced that the University of Nebraska Medical Center (UNMC) has commenced patient enrollment for its pivotal Phase III TIGeR-PaC clinical trial. This study is investigating RenovoGem, a drug-device combination utilizing the company's Trans-Arterial Micro-Perfusion (TAMP) therapy platform, to treat Locally Advanced Pancreatic Cancer (LAPC). The trial aims to compare the effectiveness of TAMP's targeted chemotherapy delivery to the current standard-of-care, systemic intravenous chemotherapy. The trial hopes to improve patient outcomes by enabling higher drug concentrations to reach the tumor, potentially leading to better survival rates and fewer side effects.

RenovoRx, a clinical-stage biopharmaceutical company, has appointed Ryan Witt as Senior Vice President, Head of Corporate Strategy and Partnerships. This new role underscores the company's commitment to exploring and executing clinical and commercial opportunities for its RenovoGem™ product, currently in Phase III trials, and its FDA-cleared drug-delivery device. Witt, who has over 15 years of experience, has previously served in various strategic leadership roles, including Chief Business Officer at Spinogenix and Chief Operating Officer at Immix Biopharma. His appointment aims to leverage his expertise to advance RenovoRx's pivotal Phase III clinical trial, expand into additional cancer treatments, and explore new business opportunities.

RenovoRx has raised $17.2 million in gross proceeds since early 2024, enabling the advancement of its pivotal Phase III TIGeR-PaC clinical trial for Locally Advanced Pancreatic Cancer (LAPC) and the expansion of its drug-delivery platform into additional cancer indications. The company, led by CEO Shaun Bagai, aims to improve patient outcomes with its precision oncology therapies. Recent promotions within the management team and publications supporting the Trans-Arterial Micro-Perfusion (TAMP) platform demonstrate progress. A second interim analysis for the TIGeR-PaC trial is expected by late 2024, following the completion of the first interim analysis in March 2023.

RenovoRx has announced the publication of pre-clinical studies demonstrating the efficacy of its Trans-Arterial Micro-Perfusion (TAMP) therapy platform.

The data, published in the Journal of Vascular Interventional Radiology, reveals a 100-fold increase in local tissue concentration of chemotherapy when using TAMP compared to conventional intravenous delivery.

TAMP aims to improve the safety and efficacy of oncology therapies by delivering drugs directly to solid tumors, potentially reducing systemic toxicity and widening the therapeutic window.

The studies were co-authored by experts from the Oregon Health and Science University, University of Pittsburgh Hillman Cancer Center, and RenovoRx.

The platform could address unmet needs in localized drug delivery, pending validation from ongoing Phase III clinical trials.

RenovoRx, a clinical-stage biopharmaceutical company (Nasdaq: RNXT), will take part in a fireside chat at the A.G.P. Virtual Healthcare Company Showcase on May 21, 2024. CEO Shaun Bagai will discuss the company's recent milestones, including raising $17.2 million through private placements. This funding will support RenovoRx's Phase III TIGeR-PaC clinical trial for its lead product, RenovoGem, aimed at treating locally advanced pancreatic cancer. The TIGeR-PaC's second interim analysis is anticipated by late 2024. The event will be moderated by Scott Henry, Managing Director at A.G.P.

RenovoRx, Inc. (RNXT) CEO Shaun R. Bagai will present at the Aegis Capital Virtual Conference on May 9, 2024. The company recently completed private placements raising $17.2 million. This funding will support the Phase III TIGeR-PaC clinical trial for RenovoGem™ in locally advanced pancreatic cancer. The second interim analysis is expected in late 2024.